Cannabinoids in the management of spasticity associated with multiple sclerosis

Anna Maria Malfitano, Maria Chiara Proto, Maurizio BifulcoDipartimento di Scienze Farmaceutiche, Universit&agrave; degli Studi di SalernoAbstract: The endocannabinoid system and cannabinoid-based treatments have been involved in a wide number of diseases. In particular, several studies sugge...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anna Maria Malfitano, Maria Chiara Proto, Maurizio Bifulco
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2f1b1e7ad19f4caf867e311d798728b4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2f1b1e7ad19f4caf867e311d798728b4
record_format	dspace
spelling	oai:doaj.org-article:2f1b1e7ad19f4caf867e311d798728b42021-12-02T02:04:35ZCannabinoids in the management of spasticity associated with multiple sclerosis1176-63281178-2021https://doaj.org/article/2f1b1e7ad19f4caf867e311d798728b42008-08-01T00:00:00Zhttp://www.dovepress.com/cannabinoids-in-the-management-of-spasticity-associated-with-multiple--a2039https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Anna Maria Malfitano, Maria Chiara Proto, Maurizio BifulcoDipartimento di Scienze Farmaceutiche, Universit&agrave; degli Studi di SalernoAbstract: The endocannabinoid system and cannabinoid-based treatments have been involved in a wide number of diseases. In particular, several studies suggest that cannabinoids and endocannabinoids may have a key role in the pathogenesis and therapy of multiple sclerosis (MS). In this study we highlight the main findings reported in literature about the relevance of cannabinoid drugs in the management and treatment of MS. An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of MS, including spasticity and pain. In this report we focus on the effects of cannabinoids in the relief of spasticity describing the main findings in vivo, in the mouse experimental allergic encephalomyelitis model of MS. We report on the current treatments used to control MS symptoms and the most recent clinical studies based on cannabinoid treatments, although long-term studies are required to establish whether cannabinoids may have a role beyond symptom amelioration in MS.Keywords: cannabinoids, multiple sclerosis, spasticity Anna Maria MalfitanoMaria Chiara ProtoMaurizio BifulcoDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 5, Pp 847-853 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Anna Maria Malfitano Maria Chiara Proto Maurizio Bifulco Cannabinoids in the management of spasticity associated with multiple sclerosis
description	Anna Maria Malfitano, Maria Chiara Proto, Maurizio BifulcoDipartimento di Scienze Farmaceutiche, Universit&agrave; degli Studi di SalernoAbstract: The endocannabinoid system and cannabinoid-based treatments have been involved in a wide number of diseases. In particular, several studies suggest that cannabinoids and endocannabinoids may have a key role in the pathogenesis and therapy of multiple sclerosis (MS). In this study we highlight the main findings reported in literature about the relevance of cannabinoid drugs in the management and treatment of MS. An increasing body of evidence suggests that cannabinoids have beneficial effects on the symptoms of MS, including spasticity and pain. In this report we focus on the effects of cannabinoids in the relief of spasticity describing the main findings in vivo, in the mouse experimental allergic encephalomyelitis model of MS. We report on the current treatments used to control MS symptoms and the most recent clinical studies based on cannabinoid treatments, although long-term studies are required to establish whether cannabinoids may have a role beyond symptom amelioration in MS.Keywords: cannabinoids, multiple sclerosis, spasticity
format	article
author	Anna Maria Malfitano Maria Chiara Proto Maurizio Bifulco
author_facet	Anna Maria Malfitano Maria Chiara Proto Maurizio Bifulco
author_sort	Anna Maria Malfitano
title	Cannabinoids in the management of spasticity associated with multiple sclerosis
title_short	Cannabinoids in the management of spasticity associated with multiple sclerosis
title_full	Cannabinoids in the management of spasticity associated with multiple sclerosis
title_fullStr	Cannabinoids in the management of spasticity associated with multiple sclerosis
title_full_unstemmed	Cannabinoids in the management of spasticity associated with multiple sclerosis
title_sort	cannabinoids in the management of spasticity associated with multiple sclerosis
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/2f1b1e7ad19f4caf867e311d798728b4
work_keys_str_mv	AT annamariamalfitano cannabinoidsinthemanagementofspasticityassociatedwithmultiplesclerosis AT mariachiaraproto cannabinoidsinthemanagementofspasticityassociatedwithmultiplesclerosis AT mauriziobifulco cannabinoidsinthemanagementofspasticityassociatedwithmultiplesclerosis
_version_	1718402700659392512

Cannabinoids in the management of spasticity associated with multiple sclerosis

Ejemplares similares